{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T12:31:39Z","timestamp":1777465899892,"version":"3.51.4"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Comprehensive Support Project for Oncological Research of Breast Cancer","award":["Comprehensive Support Project for Oncological Research of Breast Cancer (CSPOR-BC)"],"award-info":[{"award-number":["Comprehensive Support Project for Oncological Research of Breast Cancer (CSPOR-BC)"]}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","award":["Eisai"],"award-info":[{"award-number":["Eisai"]}],"id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s12282-026-01852-5","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T11:37:07Z","timestamp":1774870627000},"page":"752-760","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Minimal important differences of EORTC QLQ-C30 and QLQ-BR23 for metastatic breast cancer patients in a Japanese population: results from the RESQ trial"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0081-9115","authenticated-orcid":false,"given":"Yosuke","family":"Aoyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3103-8055","authenticated-orcid":false,"given":"Kosuke","family":"Kashiwabara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3852-5991","authenticated-orcid":false,"given":"Yuichiro","family":"Kikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4266-1117","authenticated-orcid":false,"given":"Naruto","family":"Taira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9292-5128","authenticated-orcid":false,"given":"Hirofumi","family":"Mukai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6641-9598","authenticated-orcid":false,"given":"Masato","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"1852_CR1","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365\u201376. https:\/\/doi.org\/10.1093\/jnci\/85.5.365.","journal-title":"J Natl Cancer Inst"},{"key":"1852_CR2","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1200\/JCO.1996.14.10.2756","volume":"14","author":"MA Sprangers","year":"1996","unstructured":"Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol. 1996;14:2756\u201368. https:\/\/doi.org\/10.1200\/JCO.1996.14.10.2756.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1852_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkz037","volume":"3","author":"JZ Musoro","year":"2019","unstructured":"Musoro JZ, Coens C, Fiteni F, Katarzyna P, Cardoso F, Russell NS, et al. Minimally important differences for interpreting EORTC QLQ-C30 scores in patients with advanced breast cancer. JNCI Cancer Spectr. 2019;3(3):pkz037. https:\/\/doi.org\/10.1093\/jncics\/pkz037.","journal-title":"JNCI Cancer Spectr"},{"key":"1852_CR4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ejca.2023.04.027","volume":"188","author":"JZ Musoro","year":"2023","unstructured":"Musoro JZ, Coens C, Sprangers MAG, Brandberg Y, Groenvold M, Flechtner H, et al. Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: a synthesis across 21 clinical trials involving nine different cancer types. Eur J Cancer. 2023;188:171\u201382. https:\/\/doi.org\/10.1016\/j.ejca.2023.04.027.","journal-title":"Eur J Cancer"},{"issue":"9","key":"1852_CR5","doi-asserted-by":"publisher","first-page":"e1346","DOI":"10.1634\/theoncologist.2020-0084","volume":"25","author":"MP Goetz","year":"2020","unstructured":"Goetz MP, Martin M, Tokunaga E, Park IH, Huober J, Toi M, et al. Health-related quality of life in MONARCH 3: abemaciclib plus an aromatase inhibitor as initial therapy in HR+, HER2\u2009\u2212\u2009advanced breast cancer. Oncologist. 2020;25(9):e1346\u201354.","journal-title":"Oncologist"},{"key":"1852_CR6","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1093\/annonc\/mdw139","volume":"27","author":"N Harbeck","year":"2016","unstructured":"Harbeck N, Iyer S, Turner N, Cristofanilli M, Ro J, Andr\u00e9 F, et al. Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. Ann Oncol. 2016;27:1047\u201354.","journal-title":"Ann Oncol"},{"issue":"7","key":"1852_CR7","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.annonc.2023.04.516","volume":"34","author":"G Curigliano","year":"2023","unstructured":"Curigliano G, Dunton K, Rosenlund M, Janek M, Cathcart J, Liu Y, et al. Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study. Ann Oncol. 2023;34(7):569\u201377. https:\/\/doi.org\/10.1016\/j.annonc.2023.04.516.","journal-title":"Ann Oncol"},{"issue":"5","key":"1852_CR8","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.annonc.2020.02.003","volume":"31","author":"S Adams","year":"2020","unstructured":"Adams S, Di\u00e9ras V, Barrios CH, Winer EP, Schneeweiss A, Iwata H, et al. Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer. Ann Oncol. 2020;31(5):582\u20139. https:\/\/doi.org\/10.1016\/j.annonc.2020.02.003.","journal-title":"Ann Oncol"},{"issue":"6","key":"1852_CR9","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1007\/s11136-021-03074-y","volume":"31","author":"T Kawahara","year":"2022","unstructured":"Kawahara T, Taira N, Shiroiwa T, Hagiwara Y, Fukuda T, Uemura Y, et al. Minimal important differences of EORTC QLQ-C30 for metastatic breast cancer patients: results from a randomized clinical trial. Qual Life Res. 2022;31(6):1829\u201336. https:\/\/doi.org\/10.1007\/s11136-021-03074-y.","journal-title":"Qual Life Res"},{"key":"1852_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102715","volume":"74","author":"M Takahashi","year":"2024","unstructured":"Takahashi M, Kikawa Y, Kashiwabara K, Taira N, Iwatani T, Shimozuma K, et al. Eribulin versus S-1 as first or second-line chemotherapy to assess health-related quality of life and overall survival in HER2-negative metastatic breast cancer (RESQ study): a non-inferiority, randomised, controlled, open-label, phase 3 trial. EClinicalMedicine. 2024;74:102715.","journal-title":"EClinicalMedicine"},{"key":"1852_CR11","volume-title":"The EORTC QLQ-C30 scoring manual","author":"PM Fayers","year":"2001","unstructured":"Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 scoring manual. 3rd ed. Brussels: European Organisation for Research and Treatment of Cancer; 2001.","edition":"3"},{"key":"1852_CR12","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Davis TE. Toxicology and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649\u201355.","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"1852_CR13","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","volume":"61","author":"D Revicki","year":"2008","unstructured":"Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol. 2008;61(2):102\u20139.","journal-title":"J Clin Epidemiol"},{"key":"1852_CR14","doi-asserted-by":"publisher","DOI":"10.4324\/9780203771587","volume-title":"Statistical power analysis for the behavioral sciences","author":"J Cohen","year":"1988","unstructured":"Cohen J. Statistical power analysis for the behavioral sciences. Milton Park: Routledge; 1988. https:\/\/doi.org\/10.4324\/9780203771587."},{"issue":"9","key":"1852_CR15","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/s41416-021-01531-6","volume":"125","author":"H Mukai","year":"2021","unstructured":"Mukai H, Uemura Y, Akabane H, Watanabe T, Park Y, Takahashi M, et al. Anthracycline-containing regimens or taxane versus S-1 as first-line chemotherapy for metastatic breast cancer. Br J Cancer. 2021;125(9):1217\u201325.","journal-title":"Br J Cancer"},{"issue":"5","key":"1852_CR16","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1200\/JCO.2003.05.135","volume":"21","author":"P Therasse","year":"2003","unstructured":"Therasse P, Mauriac L, Welnicka-Jaskiewicz M, et al. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide plus filgrastim as neoadjuvant treatment in locally advanced breast cancer: An EORTC-NCIC-SAKK multicenter study. J Clin Oncol. 2003;21(5):843\u201350.","journal-title":"J Clin Oncol"},{"issue":"14","key":"1852_CR17","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1200\/JCO.2002.11.005","volume":"20","author":"L Biganzoli","year":"2002","unstructured":"Biganzoli L, Cufer T, Bruning P, et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. J Clin Oncol. 2002;20(14):3114\u201321.","journal-title":"J Clin Oncol"},{"key":"1852_CR18","doi-asserted-by":"crossref","unstructured":"Kikawa Y, Uemura Y, Taira T, Kitagawa C, Maeda H, Kato H et al. A randomized study comparing electronic patient-reported outcomes monitoring with routine follow-up during trastuzumab deruxtecan treatment for inoperable or metastatic breast cancer patients: PRO-DUCE study. ASCO Annual Meeting. (2024)","DOI":"10.1200\/JCO.2024.42.16_suppl.1504"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01852-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-026-01852-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01852-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:26:52Z","timestamp":1777382812000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-026-01852-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1852"],"URL":"https:\/\/doi.org\/10.1007\/s12282-026-01852-5","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yosuke Aoyama has received honoraria for lectures from Taiho, MSD, Pfizer, Eli Lilly, Daiichi Sankyo, Eisai, Kyowa Kirin, and Chugai. Yuichiro Kikawa has received honoraria for lectures from Eisai, Daiichi Sankyo, AstraZeneca, Pfizer, Taiho, Gilead Sciences, and Eli Lilly. Naruto Taira reports receiving institutional research grants from Eisai, Chugai, Daiichi Sankyo, Kyowa Kirin, Eli Lilly, and Taiho, and has received honoraria for lectures from Eisai, Pfizer, Chugai, Daiichi Sankyo, Eli Lilly, Kyowa Kirin, AstraZeneca, MSD, Takeda, and Boehringer Ingelheim. He serves as Director of the Japanese Breast Cancer Society (JBCS). Hirofumi Mukai has received honoraria for lectures from Takeda, Daiichi Sankyo, and Taiho. Masato Takahashi has received honoraria for lectures from AstraZeneca, Eli Lilly, Eisai, MSD, and Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures involving human participants were conducted in accordance with the ethical standards of the institutional and\/or national research committees and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Informed consent was obtained from all participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}